PINK1-mediated mitophagy contributes to glucocorticoid-induced cathepsin K production in osteocytes

Prenatal hormone stress triggers embryonic cardiac hypertrophy outcome by ubiquitin-dependent degradation of mitochondrial mitofusin 2

“… 54 In addition, the suppressive effect of GCs on MFN2 expression has also been observed in other cells types and tissues. 55 , 56 , 57 Furthermore, we investigated the underlying mechanism by which CORT reduces mitochondrial MFN2 expression from a fresh perspective. We found that CORT promotes the ubiquitination of mitochondrial MFN2 at a post-transcriptional level, leading to its subsequent proteasomal degradation.…”

Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density

“…Pharmacogenomics and Personalized Medicine 2023:16 926 blood creatinine >177 mol/L; (4) Rheumatoid arthritis or took steroids or anticonvulsant for >6 months or other drugs affecting bone metabolism; (5) suffered from gastric ulcer, Crohn's disease and chronic dysentery in recent two years; (6) non-hereditary nerve or muscle disease affecting BMD; (7) sequelae of heart or brain disease affecting limb movements; (8) fracture of non-brittle fracture sites (nose, toes, skull, mandible and phalanges) and fracture resulting from severe trauma; (9) all malignancies; (10) bilateral oophorectomy before 45 years of age; (11) menopause before 40 years of age; (12) brittle fracture with no accurate medical history and X-ray image; (13) previous treatment with calcium, vitamin D, active vitamin D, bisphosphonate, sodium fluoride, calcitonin, sodium fluoride, a selective estrogen receptor modulator, strontium ranelate, or the recombinant form of PTH or current use of hormone replacement therapy; (14) Active gastric or duodenal ulcer, reflux esophagitis or any other disease contraindicated for alendronate use; (15) unable to stand or sit for half an hour; ( 16) BMI <18 kg/m 2 or >30 kg/m 2 ; (17) hypocalcemia (serum calcium (Ca) < 2.08 mmol/l) or hypophosphatemia 130 (serum phosphorus (P) < 0.80 mmol/l); (18) increased serum parathyroid hormone (PTH) levels (normal values: 15-65 pg/mL); (19) inability to understand and follow-up regularly.…”

“…[12][13][14] Osteoporosis and some other diseases of the bones are associated with genetic changes in CTSK. [14][15][16] Seven genes encoding CTSK were found to be mutated in eight families with pycnodysostosis. [17][18][19] These mutations can inhibit the degradation of collagen type I so as to increase BMD.…”

2023 January issue Journal of Orthopaedic Translation

“…Yuan et al. found that PINK1 (PTEN-induced putative kinase 1)-mediated mitophagy promoted the production of cathepsin K in osteocytes and thereby the extracellular matrix degradation, thus mediating the GC-induced bone loss [ 14 ]. Osteogenesis imperfecta (OI) is a congenital disorder characterized by muscle defect and skeletal fragility, and no cure is yet available.…”